Prognosis and Safety of Neoadjuvant Therapy Plus Surgery versus Upfront Surgery in Patients with Resectable Hepatocellular Carcinoma at CNLC Ib-IIa Stage: A Propensity Score Matching Study

Introduction

High-level evidence for neoadjuvant therapy in China Liver Cancer Staging (CNLC) Ib-IIa hepatocellular carcinoma (HCC) is lacking, and treatment duration is not standardized. This study aimed to compared prognosis and safety between neoadjuvant therapy plus surgery and upfront surgery, and to explore better neoadjuvant treatment duration, in CNLC Ib-IIa HCC patients.